MSB2311 is a 2nd generation PD-L1 antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumor penetration.
It is the first clinical asset generated by MabSpace's proprietary immune tolerance breaking technology platform.
This study, MSB2311-CSP-001, is a first-in-human, open-label, Phase 1 dose-escalation study of MSB2311, a humanized anti-PD-L1 monoclonal antibody in patients with advanced solid tumors.
A separate China Phase 1 study with several disease expansion cohorts to evaluate preliminary efficacy is at the final stage of regulatory review, and if approved, is expected to be initiated soon.
MabSpace Biosciences specializes in discovering and developing innovative antibody therapeutics using its proprietary immune tolerance breaking technology platform.
The company has built a pipeline in immune-oncology, ophthalmology, and nephrology. It is headquartered in Hong Kong, with a fully-integrated antibody discovery and development facility in Biobay, Suzhou Industrial Park, China.
Micreos passes US FDA approval for PhageGuard-E to combat E. Coli O157
Valeo Pharma signs strategic agreement with Besins Healthcare
Roivant Sciences launches Respivant Sciences
US FDA grants rare paediatric disease designation to Cellectar Biosciences' CLR 131
Janssen submits erdafitinib's NDA with the US FDA for the treatment of metastatic urothelial cancer
Positive Cytisine Data Published in International Journal of Drug Policy
FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Disease